Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Unresectable Hepatocellular Carcinoma Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High incidence rate of liver carcinoma
5.1.1.2. Increasing cases of liver cancer
5.1.1.3. Major application of chemotherapy
5.1.2. Restraints
5.1.2.1. Limited diagnosis of unresectable hepatocellular carcinoma
5.1.3. Opportunities
5.1.3.1. Advancements for new treatment and therapies
5.1.4. Challenges
5.1.4.1. Limited effects of current therapeutics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Unresectable Hepatocellular Carcinoma Market, by Systemic Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Molecularly Targeted Therapy

7. Unresectable Hepatocellular Carcinoma Market, by End User
7.1. Introduction
7.2. Cancer Centers
7.3. Hospitals
7.4. Research institutes
7.5. Specialty Clinics

8. Americas Unresectable Hepatocellular Carcinoma Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Unresectable Hepatocellular Carcinoma Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Astrazeneca PLC
12.1.2. Bayer AG
12.1.3. Bristol-Myers Squibb Company
12.1.4. Celgene Corporation
12.1.5. Chugai Pharmaceutical Co. Ltd
12.1.6. Eisai Co. Ltd
12.1.7. Eli Lilly and Company
12.1.8. F. Hoffmann-La Roche Ltd
12.1.9. Glaxosmithkline PLC
12.1.10. Merck & Co. Inc.
12.1.11. Novartis AG
12.1.12. Pfizer Inc.
12.1.13. Pharmaxis Ltd
12.1.14. Sanofi S.A.
12.1.15. Sumitomo Dainippon Pharma Co., Ltd
12.2. Key Product Portfolio

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



List of Figures

FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
FIGURE 2. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET DYNAMICS
FIGURE 7. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2030 (%)
FIGURE 8. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MOLECULARLY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 10. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 101. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 102. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET LICENSE & PRICING